The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Event
  • Legal

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • IDI Consulting Supports Crohn's & Colitis Foundation as Silver Sponsor for Pittsburgh Take Steps Walk
  • This Weekend Causeway Cove Country BBQ & Music Festival Returns for Fourth Year, Celebrating America's 250th Anniversary on the Water
  • Save 10 Percent Off Summer Stays at KeysCaribbean Resorts
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Senco Home Services Expands Residential Construction Services
  • Ricci's Painting & Contracting Expands Home Transformation Services
  • United Way and Community Partners Launch Relief Fund to Support Victims of the Six-Alarm Fire in Allentown
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
  • Connecta Satellite Solutions Ready to Support Emergency Communications Following the Venezuela Earthquake
  • Rare 1933 Harold Weston painting will be auctioned to benefit the Keene Valley Library
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • HomeCentris Home Health Achieves 5-Star CMS Rating
  • Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
  • Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • Cango Mobility x Hikvision Announce Strategic Partnership
  • Institute of Emerging Minds Publishes Framework for Glymphatic Clearance and Cognitive Optimization
  • HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
  • Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
  • Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
  • George Martinez Completes Community Re-distribution Initiative, Returning $5,000 In Campaign Resources To Anchorage Nonprofits
  • Mister Omaha Tries The Turf At Lone Star Park
  • Andrew D. Levine Releases The Lily Network, an Indian Noir Mystery of Power, Paperwork & Murder
  • The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Joulescope JS320 Launches to Help Engineers Develop Battery-Powered Devices with Greater Confidence

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 149
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • From Broken to Soaring Week 40
  • A Brave Little Hero with Four Paws
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • A Foundational Claim in Human Secrecy Goes Public
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Dave's Auto Services Sponsors Night of Racing at Action Track USA in Kutztown PA
  • Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing

Similar on PennZone

  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us